Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials
- PMID: 11113952
- DOI: 10.1002/1097-0258(20001215)19:23<3171::aid-sim619>3.0.co;2-t
Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials
Abstract
For many biomarkers, the range (L,R) over which they can be quantified is restricted by technical limitations, leading to some measurements that are left or right censored. However, despite the widespread availability of statistical methods for the analysis of censored data, many studies use an imputed value for censored measurements (for example, replacing a value <L by L, or by L/2). Commonly, an analysis that ignores such imputation is then used. In clinical trials, this leads to bias and a loss of power in evaluating treatment effects. In this paper, a review of appropriate statistical methods for parametric and non-parametric analysis of such measurements is presented. This includes methods for situations in which baseline measurements are available. New results concerning design issues such as sample size determination are also presented. The paper is illustrated using two examples of studies that included censored measurements of viral load in HIV-infected subjects.
Similar articles
-
Modelling HIV-RNA viral load in vertically infected children.Stat Med. 2004 Mar 15;23(5):769-81. doi: 10.1002/sim.1615. Stat Med. 2004. PMID: 14981674
-
Inference for a linear regression model with an interval-censored covariate.Stat Med. 2003 Feb 15;22(3):409-25. doi: 10.1002/sim.1326. Stat Med. 2003. PMID: 12529872
-
Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data.J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):286-92. doi: 10.1097/00126334-200403010-00010. J Acquir Immune Defic Syndr. 2004. PMID: 15076244 Review.
-
Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit.Stat Med. 2005 Jan 30;24(2):211-28. doi: 10.1002/sim.1833. Stat Med. 2005. PMID: 15558832
-
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.HIV Med. 2009 Oct;10(9):527-35. doi: 10.1111/j.1468-1293.2009.00724.x. HIV Med. 2009. PMID: 19785663 Review.
Cited by
-
Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus.Nephrol Dial Transplant. 2015 Apr;30(4):599-606. doi: 10.1093/ndt/gfv012. Epub 2015 Feb 3. Nephrol Dial Transplant. 2015. PMID: 25648911 Free PMC article.
-
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31. Lancet Infect Dis. 2011. PMID: 21288774 Free PMC article. Clinical Trial.
-
Childhood adiposity and adolescent sex steroids in the Exploring Perinatal Outcomes among Children study.Clin Endocrinol (Oxf). 2019 Oct;91(4):525-533. doi: 10.1111/cen.14058. Epub 2019 Jul 14. Clin Endocrinol (Oxf). 2019. PMID: 31278867 Free PMC article.
-
Bayesian Empirical Likelihood Methods for Quantile Comparisons.J Korean Stat Soc. 2017 Dec;46(4):518-538. doi: 10.1016/j.jkss.2017.03.002. Epub 2017 Apr 10. J Korean Stat Soc. 2017. PMID: 29335668 Free PMC article.
-
HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.AIDS. 2014 Mar 13;28(5):739-43. doi: 10.1097/QAD.0000000000000150. AIDS. 2014. PMID: 24326356 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical